Download MBD3-deficient embryonic stem cell line

MBD3‐deficient embryonic stem cell line Researchers from the University of Edinburgh have generated a pluripotent (murine) embryonic stem cell line and have shown that these MBD3‐deficient stem cells are maintained in the absence of any exogenous factors (e.g. serum or LIF). A central goal of stem cell research is to maintain and grow pluripotent stem cells to study the signals that direct cell specialisation and how the choice between self‐renewal and cell specialisation is determined. This is critical for developing therapeutic stem cell lines. Currently, in vitro pluripotency is achieved by growing stem cells in the presence of LIF and STATs or feeder cells. Deletion of MBD3 produces reliable and reproducible (murine) embryonic stem cells that are maintained in the absence of any exogenous factors. Additionally, these cells can be easily driven to differentiate into identifiable bone, muscle, skin, fat and neuronal tissue by simple transfection of MBD3 back into the cells. Benefits 
Ease of use ‐ MBD3 expression can be restored by simple transfection of the gene back into the cells 
A reliable population of embryonic stem cells free from any exogenous factors e.g. LIF, STATs or feeder cells 
A reliable population of embryonic stem cells proven to differentiation into distinguishable tissues including skin, muscle, fat and neuronal tissue Commercial Offering The University of Edinburgh is seeking licensees to sell the MBD3 cell line as a reagent for research use. The technology is also available for in‐house R&D in the field of compound screening Disruption of MBD3 has generated a reliable population of pluripotent or research into signals and factors that control (murine) stem cells maintained in the absence of any exogenous cell specialisation. factors. Restoring MBD3 expression, by simple gene transfection, enables differentiation into easily distinguishable tissues, including Order it now! skin, muscle, fat and neuronal tissue. These results establish MDB3 as This University of Edinburgh technology can be a critical determinant for lineage commitment in embryonic stem licensed directly under a standard non‐exclusive cells. license agreement at: https://licensing.eri.ed.ac.uk Applications MBD3 null embryonic stem cells can be used to develop: 
specific stem cell lines for high‐throughput screening of therapeutic compounds; 
transgenics for the study of specific diseases; and/or 
specific therapeutic stem cell lines for replacement therapies to treat diseases and injuries such as Parkinson’s disease. Contact Shona Cunningham Telephone: +44 (0)131 650 6430 Email: [email protected] www.research‐innovation.ed.ac.uk